---
title: "Sito Bio: Plans to repurchase company shares for 15 million to 30 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278352835.md"
description: "36Kr learned that Sito Bio announced plans to repurchase company shares through centralized bidding, with a total repurchase amount not less than 15 million yuan and not exceeding 30 million yuan. The repurchase price will not exceed 21.98 yuan per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan"
datetime: "2026-03-09T08:08:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278352835.md)
  - [en](https://longbridge.com/en/news/278352835.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278352835.md)
generator: "portal-rs"
---

# Sito Bio: Plans to repurchase company shares for 15 million to 30 million yuan

36Kr learned that Sito Bio announced plans to repurchase company shares through centralized bidding, with a total repurchase amount not less than 15 million yuan and not exceeding 30 million yuan. The repurchase price will not exceed 21.98 yuan per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan

### Related Stocks

- [300583.CN](https://longbridge.com/en/quote/300583.CN.md)

## Related News & Research

- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [CASAN corrects board minutes to refer to public note issuance via Banco Bocom BBM](https://longbridge.com/en/news/296411185.md)
- [Festi hf.: Transactions in relation to a share repurchase programme - week 33](https://longbridge.com/en/news/296076530.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety](https://longbridge.com/en/news/296374826.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**